N Jabri, DS Schalch, SL Schwartz, JS Fischer … - Diabetes, 1994 - Am Diabetes Assoc Data from studies in diabetic rodents and evidence from clinical situations of
severe resistance to insulin suggest that insulin-like growth factor I (IGF-I)
is able to at least partly overcome insulin resistance. To assess the ... Cited by 79 - Related articles - BL Direct - All 4 versions
DS Schalch, NJ Turman, VS Marcsisin, M … - Journal of Clinical Endocrinology & Metabolism, 1993 - Endocrine Soc Page 1. 0021-972x/93/77@3-1563$03.00/0 Journal of Clinical Endocrinology and Metabolism
Copyright 0 1993 by The Endocrine Society Vol. 17, No. 6 Printed in USA ... Cited by 40 - Related articles - BL Direct - All 4 versions
T Quattrin, K Thrailkill, L Baker, J Litton, K … - Diabetes Care, 1997 - Am Diabetes Assoc OBJECTIVE: To examine if dual replacement with insulin and rhIGF-I, recombinant
human insulin-like growth factor I (rhIGF-I) may be safe and result in improved
metabolic control and reduced insulin usage. RESEARCH DESIGN AND METHODS: ... Cited by 33 - Related articles - BL Direct - All 6 versions
- ►annals.org CA Bondy, LE Underwood, DR Clemmons, HP … - Annals of internal medicine, 1994 - Am Coll Physicians Insulin-like growth factor I (IGF-I) has acute insulin-like metabolic effects
and long-term anabolic actions. The therapeutic potential of recombinant human
IGF-I treatment is being investigated in various growth hormone-resistant ... Cited by 91 - Related articles - BL Direct - All 3 versions
H Kuzuya, N Matsuura, M Sakamoto, H … - Diabetes, 1993 - Am Diabetes Assoc Extreme insulin resistance occurs in patients with primary defects in insulin
action at the receptor or postreceptor levels. The condition commonly is
associated with acanthosis nigricans and ovarian masculinization. Despite a ... Cited by 90 - Related articles - BL Direct - All 5 versions
AL Usala, T Madigan, B Burguera, W Cefalu, … - Journal of Clinical Endocrinology & Metabolism, 1994 - Endocrine Soc Page 1. GiI21-972x/94/7902-0435$03.00/0 Journal of Clinical Endocrmology and Metabolism
Copyright 0 1994 by The Endocrine Society Vol. 79, No. 2 Printed in USA ... Cited by 15 - Related articles - BL Direct - All 4 versions
CL Acerini, CM Patton, MO Savage, A Kernell … - The Lancet, 1997 - Elsevier With a dose of 40 μg/kg rhlGF-l daily, we found significant reductions in HbA
1c compared with placebo (p=O.O3), without changes in body-mass index, rate of
hypoglycaemia, insulin dose, or circulating concentrations of IGF-binding ... Cited by 78 - Related articles - BL Direct - All 9 versions
- ►nih.gov [PDF] PD Zenobi, SE Jaeggi-Groisman, WF Riesen, … - Journal of Clinical Investigation, 1992 - pubmedcentral.nih.gov Hyperglycemia, hyperinsulinemia, and insulin resistance cause vascular disease
in type 2 diabetes mellitus. Dietary treatment alone often fails and oral drugs
or insulin enhance hyperinsulin- emia. In previous studies, an intravenous ... Cited by 100 - Related articles - BL Direct - All 7 versions
TD Cheetham, J Jones, AM Taylor, J Holly, … - Diabetologia, 1993 - Springer Summary. Type i (insulin-dependent) diabetes mellitus in adolescence is
associated with reduced levels of insulin-like growth factor I, elevated growth
hormone concentrations and insulin resistance. In order to determine ... Cited by 59 - Related articles - BL Direct - All 4 versions
AC Moses, SC Young, LA Morrow, M O'brien … - Diabetes, 1996 - Am Diabetes Assoc Insulin resistance is a major factor in the pathophysiology of type II diabetes
and a major impediment to successful therapy. The identification of treatments
that specifically target insulin resistance could improve diabetes ... Cited by 138 - Related articles - BL Direct - All 4 versions
